Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,159 Cr
verified against source
Revenue YoY
25%
reported change
EBITDA
₹296 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Global Health (Medanta) reported a strong Q4 FY26 with revenue of ₹1,196 crore (+25% YoY) and PAT of ₹147 crore (+14% YoY), driven by robust volume growth (IPD +23%, OPD +27%) and improving realizations (ARPOB +5% to ₹66,687). The Noida hospital ramp-up is on track, with Q4 EBITDA loss narrowing to ₹236 crore from ₹320 crore in Q3, and management expects breakeven in H2 FY27. Mature hospitals delivered steady margins of 26.7%, while developing hospitals (ex-Noida) posted 33% revenue growth and 32.4% margins. The company guided for ₹800-900 crore capex in FY27 and plans to add ~500 beds with minimal capex. Key risks include competitive intensity in Gurugram from new hospital openings and potential delays in greenfield projects.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects Noida hospital to break even in the second half of FY27, with occupancy reaching 40-45%.
- Total capex for FY27 is expected to be in the range of ₹800-900 crore, with FY28 capex at ₹600-700 crore.
- The company expects to add around 500 beds across existing hospitals with minimal capex investment in the short term.
- Medanta plans to add approximately 2,700 beds through five greenfield projects over the next 3-4 years, with total project capex of ~₹45,000 million over 5 years.
Risks flagged
- New hospitals opening in Gurugram could increase competition for patients and clinical talent, potentially impacting occupancy and margins.
- Noida's breakeven timeline depends on occupancy reaching 40-45%; delays in empanelments or patient flow could extend losses.
- International patient revenue faces short-term challenges due to the situation in the Middle East, which could impact growth.
- Large greenfield projects (Delhi, Mumbai) may take 3+ years, with potential delays in regulatory approvals or construction, pushing revenue contribution beyond FY30.
Key quotes
- We do expect this unit to break even during the course of this year but I would say that probably we would look at the second half of next year rather than to look at giving you a number on quarter two.
- Our mature hospitals are largely stable and we are working to see if we can tweak out inefficiencies wherever we can.
- We are not overly worried either on the demand side or on our ability to attract or retain clinical talent.
Research modules